A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization.

Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2015

At a glance

  • Drugs Lacosamide (Primary) ; Antiepileptic drugs
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 27 Jan 2010 Primary endpoint 'Seizure frequency' has been met.
    • 27 Jan 2010 Primary endpoint 'response rate' has been met.
    • 27 Jan 2010 Results were published in Epilepsia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top